Five-year data from the PARTNER 3 trial showed that among low-risk patients with severe, symptomatic aortic stenosis, ...

Edwards Lifesciences (NYSE: EW) today announced new data demonstrating long-term benefits with its Sapien heart valve system.

The companies have teamed to develop an alternative to TAVR that combines the benefits of a less-invasive procedure with the ...

Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data, which showed superior clinical ...

A Delaware judge correctly interpreted transcatheter aortic valve-replacement device patents that were asserted against ...

Investing.com -- Edwards Lifesciences (NYSE:EW) stock rose 4.5% following the presentation of new data showing long-term benefits and valve performance of its SAPIEN 3 TAVR.

Edwards Lifesciences Corp (EW) has reached a new 52-week high, with its stock price climbing to 83.02 USD. According to InvestingPro data, the company maintains strong financial health with a "GOOD" ...

Edwards Lifesciences Corp. (($EW)) announced an update on their ongoing clinical study. Study Overview: Edwards Lifesciences Corp. is conducting ...

Edwards Lifesciences Corp. (($EW)) announced an update on their ongoing clinical study. Edwards Lifesciences Corp. is collaborating with World ...

The data are largely in line with those seen at 5 years, but the follow-up reassures there’s no concern about valve ...

Patients in Northwest Georgia and Southeast Tennessee are accessing care once found only in larger metro areas — thanks to ...

Reaching participants through retail pharmacies, the study speaks to how much VHD goes underrecognized—with a few surprises.